TABLE 1.

Validation of the combination of MYC, TP53^R249S, and KRAS^G12D for transforming PHHs into HCC.

Hepatocytes a OC b	PHH1 (AKB)	PHH2 (XSM)	PHH3 (ANG)	In total d
MTK	6/10 c	4/6	4/6	14/22
MT	1/6	1/3	0/3	2/12
TK	0/3	0/3	0/3	0/9
MK	0/3	0/3	0/3	0/9
Mock	0/3	0/3	0/3	0/9

^a Hepatocytes: PHHs from three donors, including PHH1 (AKB, female, 39 years old), PHH2 (XSM, female, 59 years old), and PHH3 (ANG, male, 3 months old), were purchased from Bioreclamation IVT (Baltimore, MD, USA) and were used in the experiment.

^b OC: A cocktail of lentivirus containing different combinations of oncogenic candidates (M for MYC, T for TP53R249S, and K for KRASG12D) were transduced into PHHs from different donors. Mock: lentivirus containing EGFP only.

^c 6/10: The frequency of mice that developed iHCC in the group where PHHs from different donors (PHH1~PHH3) were transduced with indicated combination of oncogenic candidates. For example, 6 out of 10 mice, in which PHHs from the donor PHH1 were transduced with MTK and were transplanted, were observed bearing tumors.

^d In total: ***P < 0.001 for MTK‐ versus MT/Mock‐transduced PHH by one‐way ANOVA with Tukey's multiple comparison test; data are presented as the mean ± SD.